![logo](/logos/002873.SZ.webp)
Guiyang Xintian Pharmaceutical Co.,Ltd.
SZSE:002873.SZ
11.54 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 953.982 | 1,087.673 | 969.844 | 750.946 | 773.337 | 694.259 | 681.714 | 633.186 | 521.911 | 454.126 | 406.127 | 330.089 |
Cost of Revenue
| 218.758 | 247.287 | 201.157 | 165.328 | 162.58 | 145.713 | 132.608 | 115.296 | 85.722 | 81.72 | 85.765 | 78.556 |
Gross Profit
| 735.224 | 840.387 | 768.687 | 585.618 | 610.757 | 548.546 | 549.107 | 517.89 | 436.189 | 372.405 | 320.362 | 251.533 |
Gross Profit Ratio
| 0.771 | 0.773 | 0.793 | 0.78 | 0.79 | 0.79 | 0.805 | 0.818 | 0.836 | 0.82 | 0.789 | 0.762 |
Reseach & Development Expenses
| 38.135 | 21.585 | 20.377 | 13.295 | 21.101 | 31.833 | 23.083 | 13.916 | 13.083 | 11.238 | 1.782 | 1.3 |
General & Administrative Expenses
| 50.449 | 45.567 | 53.848 | 44.13 | 54.856 | 58.068 | 39.549 | 34.373 | 33.088 | 32.616 | 36.138 | 20.423 |
Selling & Marketing Expenses
| 437.539 | 531.978 | 471.824 | 365.868 | 381.859 | 347.36 | 385.928 | 365.41 | 305.613 | 258.864 | 237.687 | 179.964 |
SG&A
| 487.988 | 577.545 | 525.671 | 409.998 | 436.714 | 405.428 | 425.477 | 399.782 | 338.701 | 291.48 | 273.826 | 200.387 |
Other Expenses
| -1.326 | 102.432 | 85.534 | 69.671 | 62.565 | 39.253 | -0.098 | 14.218 | 4.964 | 2.681 | 3.342 | 4.889 |
Operating Expenses
| 631.431 | 701.562 | 631.582 | 492.964 | 520.38 | 476.514 | 478.015 | 442.485 | 376.678 | 323.994 | 292.851 | 216.798 |
Operating Income
| 93.743 | 122.167 | 117.114 | 86.356 | 83.435 | 74.585 | 74.711 | 61.618 | 43.083 | 34.411 | 13.546 | 25.509 |
Operating Income Ratio
| 0.098 | 0.112 | 0.121 | 0.115 | 0.108 | 0.107 | 0.11 | 0.097 | 0.083 | 0.076 | 0.033 | 0.077 |
Total Other Income Expenses Net
| -1.326 | -0.572 | -0.465 | -2.414 | -0.391 | 6.78 | -0.098 | 2.498 | 4.614 | 2.681 | 2.958 | 4.859 |
Income Before Tax
| 92.417 | 121.595 | 116.648 | 83.942 | 83.044 | 81.365 | 74.613 | 64.115 | 47.697 | 37.092 | 16.504 | 30.369 |
Income Before Tax Ratio
| 0.097 | 0.112 | 0.12 | 0.112 | 0.107 | 0.117 | 0.109 | 0.101 | 0.091 | 0.082 | 0.041 | 0.092 |
Income Tax Expense
| 11.546 | 5.493 | 16.043 | 9.839 | 12.178 | 10.97 | 8.496 | 7.046 | 5.687 | 3.968 | 1.409 | 3.976 |
Net Income
| 80.871 | 111.519 | 99.476 | 72.546 | 71.422 | 70.975 | 66.117 | 57.069 | 42.01 | 33.124 | 15.095 | 26.393 |
Net Income Ratio
| 0.085 | 0.103 | 0.103 | 0.097 | 0.092 | 0.102 | 0.097 | 0.09 | 0.08 | 0.073 | 0.037 | 0.08 |
EPS
| 0.35 | 0.51 | 0.45 | 0.33 | 0.32 | 0.31 | 0.32 | 0.33 | 0.24 | 0.19 | 0.087 | 0.15 |
EPS Diluted
| 0.33 | 0.48 | 0.41 | 0.31 | 0.32 | 0.31 | 0.32 | 0.33 | 0.24 | 0.19 | 0.087 | 0.15 |
EBITDA
| 124.902 | 162.812 | 159.153 | 109.158 | 108.608 | 101.036 | 84.969 | 89.277 | 70.591 | 55.594 | 30.677 | 39.571 |
EBITDA Ratio
| 0.131 | 0.15 | 0.164 | 0.145 | 0.14 | 0.146 | 0.125 | 0.141 | 0.135 | 0.122 | 0.076 | 0.12 |